(R)-(+)-Linoleyl-1'-Hydroxy-2'-Propylamide |
A homolog of LOEA, characterized by the addition of an (R)-α-methyl… |
10 mg |
9001233-10 |
More Info
|
(R)-(+)-Linoleyl-1'-Hydroxy-2'-Propylamide |
A homolog of LOEA, characterized by the addition of an (R)-α-methyl… |
5 mg |
9001233-5 |
More Info
|
15(R)-Lipoxin A4 |
An aspirin-triggered lipoxin that inhibits LTB4-induced chemotaxis, adhere… |
100 µg |
90415-100 |
More Info
|
15(R)-Lipoxin A4 |
An aspirin-triggered lipoxin that inhibits LTB4-induced chemotaxis, adhere… |
25 µg |
90415-25 |
More Info
|
15(R)-Lipoxin A4 |
An aspirin-triggered lipoxin that inhibits LTB4-induced chemotaxis, adhere… |
250 µg |
90415-250 |
More Info
|
15(R)-Lipoxin A4 |
An aspirin-triggered lipoxin that inhibits LTB4-induced chemotaxis, adhere… |
50 µg |
90415-50 |
More Info
|
(R)-Lisofylline |
A potent inhibitor of the generation of phosphatidic acid (IC50 = 0.6 &mic… |
1 mg |
13616-1 |
More Info
|
(R)-Lisofylline |
A potent inhibitor of the generation of phosphatidic acid (IC50 = 0.6 &mic… |
10 mg |
13616-10 |
More Info
|
(R)-Lisofylline |
A potent inhibitor of the generation of phosphatidic acid (IC50 = 0.6 &mic… |
5 mg |
13616-5 |
More Info
|
RM 133-3 |
An ionizable cationic lipid; has been used in the formation of LNPs for th… |
10 mg |
38917-10 |
More Info
|
RM 133-3 |
An ionizable cationic lipid; has been used in the formation of LNPs for th… |
25 mg |
38917-25 |
More Info
|
RM 133-3 |
An ionizable cationic lipid; has been used in the formation of LNPs for th… |
5 mg |
38917-5 |
More Info
|
RM 137-15 |
An ionizable cationic lipid; has been used in the formation of LNPs; LNPs… |
10 mg |
38918-10 |
More Info
|
RM 137-15 |
An ionizable cationic lipid; has been used in the formation of LNPs; LNPs… |
25 mg |
38918-25 |
More Info
|
RM 137-15 |
An ionizable cationic lipid; has been used in the formation of LNPs; LNPs… |
5 mg |
38918-5 |
More Info
|
R-(-)-Mandelic Acid |
A synthetic intermediate useful for pharmaceutical synthesis. |
100 g |
10007128-100 |
More Info
|
R-(-)-Mandelic Acid |
A synthetic intermediate useful for pharmaceutical synthesis. |
25 g |
10007128-25 |
More Info
|
R-(-)-Mandelic Acid |
A synthetic intermediate useful for pharmaceutical synthesis. |
250 g |
10007128-250 |
More Info
|
R-(-)-Mandelic Acid |
A synthetic intermediate useful for pharmaceutical synthesis. |
50 g |
10007128-50 |
More Info
|
RMC-4550 |
A SHP-2 inhibitor (IC50 = 1.55 nM); selective for SHP-2 over a panel of 14… |
1 mg |
31011-1 |
More Info
|
RMC-4550 |
A SHP-2 inhibitor (IC50 = 1.55 nM); selective for SHP-2 over a panel of 14… |
10 mg |
31011-10 |
More Info
|
RMC-4550 |
A SHP-2 inhibitor (IC50 = 1.55 nM); selective for SHP-2 over a panel of 14… |
25 mg |
31011-25 |
More Info
|
RMC-4550 |
A SHP-2 inhibitor (IC50 = 1.55 nM); selective for SHP-2 over a panel of 14… |
5 mg |
31011-5 |
More Info
|
RMC-4630 |
A SHP-2 inhibitor |
1 mg |
38772-1 |
More Info
|
RMC-4630 |
A SHP-2 inhibitor |
10 mg |
38772-10 |
More Info
|
RMC-4630 |
A SHP-2 inhibitor |
5 mg |
38772-5 |
More Info
|
RMC-4630 |
A SHP-2 inhibitor |
500 µg |
38772-500 |
More Info
|
(R)-(-)-Mellein |
A dihydroisocoumarin compound with a variety of biological activities incl… |
10 mg |
10311-10 |
More Info
|
(R)-(-)-Mellein |
A dihydroisocoumarin compound with a variety of biological activities incl… |
100 mg |
10311-100 |
More Info
|
(R)-(-)-Mellein |
A dihydroisocoumarin compound with a variety of biological activities incl… |
5 mg |
10311-5 |
More Info
|
(R)-(-)-Mellein |
A dihydroisocoumarin compound with a variety of biological activities incl… |
50 mg |
10311-50 |
More Info
|
(R)-Mephenytoin |
The (R) enantiomer of mephenytoin; can be demethylated by CYP2C9 to form t… |
1 mg |
25891-1 |
More Info
|
(R)-Mephenytoin |
The (R) enantiomer of mephenytoin; can be demethylated by CYP2C9 to form t… |
10 mg |
25891-10 |
More Info
|
(R)-Mephenytoin |
The (R) enantiomer of mephenytoin; can be demethylated by CYP2C9 to form t… |
25 mg |
25891-25 |
More Info
|
(R)-Mephenytoin |
The (R) enantiomer of mephenytoin; can be demethylated by CYP2C9 to form t… |
5 mg |
25891-5 |
More Info
|
R-1 Methanandamide |
A potent CB1 receptor agonist in the methanandamide series; selective for… |
10 mg |
90070-10 |
More Info
|
R-1 Methanandamide |
A potent CB1 receptor agonist in the methanandamide series; selective for… |
25 mg |
90070-25 |
More Info
|
R-1 Methanandamide |
A potent CB1 receptor agonist in the methanandamide series; selective for… |
5 mg |
90070-5 |
More Info
|
R-1 Methanandamide |
A potent CB1 receptor agonist in the methanandamide series; selective for… |
50 mg |
90070-50 |
More Info
|
R-2 Methanandamide |
A CB analog with a methyl group in the (R) configuration at C-2 of the eth… |
10 mg |
90074-10 |
More Info
|
R-2 Methanandamide |
A CB analog with a methyl group in the (R) configuration at C-2 of the eth… |
25 mg |
90074-25 |
More Info
|
R-2 Methanandamide |
A CB analog with a methyl group in the (R) configuration at C-2 of the eth… |
5 mg |
90074-5 |
More Info
|
R-1 Methanandamide Phosphate |
A water soluble prodrug analog of AEA; similar activity to AEA in the grow… |
1 mg |
10004281-1 |
More Info
|
R-1 Methanandamide Phosphate |
A water soluble prodrug analog of AEA; similar activity to AEA in the grow… |
10 mg |
10004281-10 |
More Info
|
R-1 Methanandamide Phosphate |
A water soluble prodrug analog of AEA; similar activity to AEA in the grow… |
5 mg |
10004281-5 |
More Info
|
15(R)-15-methyl Prostaglandin A2 |
A potential impurity in the production of commercial lots of bulk arbapros… |
1 mg |
10270-1 |
More Info
|
15(R)-15-methyl Prostaglandin A2 |
A potential impurity in the production of commercial lots of bulk arbapros… |
10 mg |
10270-10 |
More Info
|
15(R)-15-methyl Prostaglandin A2 |
A potential impurity in the production of commercial lots of bulk arbapros… |
5 mg |
10270-5 |
More Info
|
15(R)-15-methyl Prostaglandin D2 |
The physiological actions of PGD2 include regulation of sleep, lowering of… |
1 mg |
12720-1 |
More Info
|
15(R)-15-methyl Prostaglandin D2 |
The physiological actions of PGD2 include regulation of sleep, lowering of… |
500 µg |
12720-500 |
More Info
|